Author's response to reviews

Title: MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer

Authors:

Zsófia Pénzváltó (penzvaltozsofi@gmail.com)
András Láneczky (lanbenator@gmail.com)
Julianna Lénárt (lenartjuli@gmail.com)
Nóra Meggyesházi (meggyeshazinora@gmail.com)
Tibor Krenács (krenacst@gmail.com)
Norbert Szoboszlai (szobosz@chem.elte.hu)
Carsten Denkert (carsten.denkert@charite.de)
Imre Pete (pete@oncol.hu)
Balázs Gyorffy (zsalab2@yahoo.com)

Version: 5 Date: 9 October 2014

Author's response to reviews: see over
Dear Editorial Board,

thank you for the opportunity to revise our manuscript. Please find below a point-by-point answer to the concerns:

“Thank you for your email regarding the names of the heads of the ethics committee, however we require some further revisions to your manuscript, please could you include the ethics approval numbers/references within the methods section of your manuscript.”

We have extended the methods section with reference to the ethical approvals:

“"The institutional ethic committees (Ethikausschuss 1 am Campus Charité Mitte and Országos Onkológiai Intézet, Intézeti Kutatásetikai Bizottság - OOI IKeB), approved the study with following reference numbers: EA1/139/05 Amend 2013 (Charité) and OOI-Ált-9444-1/2013/59 (OOI).”

In addition, we have checked the format of the manuscript to adhere to the requirements of BMC Cancer. All changes are highlighted with yellow background in the manuscript.

We hope that we have sufficiently addressed the concerns and that our manuscript will now be eligible for publication.

Sincerely yours,
Balázs Győrffy